Current Neurology and Neuroscience Reports

, Volume 11, Issue 4, pp 371–378 | Cite as

Mild Cognitive Impairment in Parkinson’s Disease

Article

Abstract

Prospective studies conducted during the last decade have shown that the majority of patients with Parkinson’s disease (PD) develop dementia. In addition, using a variety of definitions and methods, more recent research suggests that approximately a quarter of PD patients without dementia have mild cognitive impairment (PD-MCI). Furthermore, several studies have shown that approximately 20% have MCI even at time of diagnosis of PD. The typical cognitive deficits include visuospatial, attentional, and executive deficits, but memory deficits have also been shown. The etiology of PD-MCI is not known, but it is likely that mechanisms known to contribute to dementia in PD (ie, limbic and cortical Lewy bodies, amyloid plaques, and cholinergic deficits) play a role, in addition to dysfunction of dopaminergic frontostriatal circuits. PD-MCI predicts a shorter time to dementia, and preliminary evidence suggests that this is particularly true for posterior cognitive deficits. There are currently no systematic clinical trials in PD-MCI.

Keywords

Parkinson’s disease Cognitive impairment Dementia Visuospatial functions Executive functions Memory Attention Imaging Biomarker Cerebrospinal fluid Pathology Dopamine Acetylcholine Noradrenaline 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.PubMedCrossRefGoogle Scholar
  2. 2.
    Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20(10):1255–63.PubMedCrossRefGoogle Scholar
  3. 3.
    Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol. 2007;254(1):38–45.PubMedCrossRefGoogle Scholar
  6. 6.
    Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–707. quiz 837.PubMedCrossRefGoogle Scholar
  7. 7.
    Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–18.PubMedCrossRefGoogle Scholar
  8. 8.
    Petersen RC. Challenges of epidemiological studies of mild cognitive impairment. Alzheimer Dis Assoc Disord. 2004;18(1):1–2.PubMedCrossRefGoogle Scholar
  9. 9.
    Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain. 2004;127(Pt 3):550–60.PubMedGoogle Scholar
  10. 10.
    Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239–45.PubMedCrossRefGoogle Scholar
  11. 11.
    • Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9(12):1200–13. This is a detailed and scholarly review of the variety of cognitive domains that are impaired in PD and their biological underpinnings.PubMedCrossRefGoogle Scholar
  12. 12.
    •• Aarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology. 2009;72(13):1121–6. This is the first study describing the frequency of MCI in an incidence cohort of nearly 200 non-medicated PD patients.PubMedCrossRefGoogle Scholar
  13. 13.
    • Elgh E, Domellof M, Linder J, et al. Cognitive function in early Parkinson’s disease: a population-based study. Eur J Neurol. 2009;16(12):1278–84. The authors report the frequency of MCI in 88 incident PD patients, most of them without medication, based on a comprehensive neuropsychological evaluation.PubMedCrossRefGoogle Scholar
  14. 14.
    • Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–9. This is an international multicenter pooled analysis of more than 1300 non-demented PD patients from eight cohorts in the United States and Europe. A common MCI classification is applied to all subjects.PubMedCrossRefGoogle Scholar
  15. 15.
    •• Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol. 2008;115(4):409–15. This is a carefully designed and skillfully conducted clinicopathologic study of the pathology underlying dementia in PD. The long-term prospective design allows for the identification of clinically relevant subgroups.PubMedCrossRefGoogle Scholar
  16. 16.
    • Adler CH, Caviness JN, Sabbagh MN, et al. Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment. Acta Neuropathol. 2010;120(6):827–8. This is the first study describing the pathology of PD patients with MCI based on prospective and detailed cognitive assessment.PubMedCrossRefGoogle Scholar
  17. 17.
    Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry. 2007;78(3):254–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Apostolova LG, Beyer M, Green AE, et al. Hippocampal, caudate, and ventricular changes in Parkinson’s disease with and without dementia. Mov Disord. 2010;25(6):687–8.PubMedGoogle Scholar
  19. 19.
    • Dalaker TO, Larsen JP, Dwyer MG, et al. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson’s disease. Neuroimage. 2009;47(4):2083–9. This paper describes MRI findings in de novo PD patients with MCI. The small sample size led to relatively low statistical power.PubMedCrossRefGoogle Scholar
  20. 20.
    • Dalaker TO, Zivadinov R, Larsen JP, et al. Gray matter correlations of cognition in incident Parkinson’s disease. Mov Disord. 2010;25(5):629–33. This paper also describes MRI findings in de novo PD patients with MCI. The small sample size led to relatively low statistical power.PubMedGoogle Scholar
  21. 21.
    • Dalaker TO, Larsen JP, Bergsland N, et al. Brain atrophy and white matter hyperintensities in early Parkinson’s disease(a). Mov Disord. 2009;24(15):2233–41. This paper also describes MRI findings in de novo PD patients with MCI. The small sample size led to relatively low statistical power.PubMedCrossRefGoogle Scholar
  22. 22.
    Grambaite R, Reinvang I, Selnes P, et al. Pre-dementia memory impairment is associated with white matter tract affection. J Int Neuropsychol Soc. 2011;17(1):143–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Unger MM, Belke M, Menzler K, et al. Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep. 2010;33(6):767–73.PubMedGoogle Scholar
  24. 24.
    Lee JE, Park HJ, Park B, et al. A comparative analysis of cognitive profiles and white-matter alterations using voxel-based diffusion tensor imaging between patients with Parkinson’s disease dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2010;81(3):320–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Huang C, Mattis P, Tang C, et al. Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage. 2007;34(2):714–23.PubMedCrossRefGoogle Scholar
  26. 26.
    • Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord. 2010;25(15):2516–23. This is one of the first studies describing amyloid imaging in patients with prospectively classified PD-MCI based on neuropsychological assessment.PubMedCrossRefGoogle Scholar
  27. 27.
    Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson’s disease dementia. Neuroimage. 2008;39(3):1027–33.PubMedCrossRefGoogle Scholar
  28. 28.
    Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79(12):1331–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1–42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia. Dement Geriatr Cogn Disord. 2006;22(3):200–8.PubMedCrossRefGoogle Scholar
  30. 30.
    • Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010;81(10):1080–6. This community-based study is one of the first studies describing CSF protein changes in de novo PD and relating it to carefully defined MCI.PubMedCrossRefGoogle Scholar
  31. 31.
    •• Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1–42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75(12):1055–61. This study for the first time explores longitudinally the predictive power of CSF Alzheimer markers on cognitive impairment in non-demented PD.PubMedCrossRefGoogle Scholar
  32. 32.
    Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213(2):315–25.PubMedCrossRefGoogle Scholar
  33. 33.
    Ohrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett. 2009;450(3):332–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain. 2010;133(Pt 3):713–26.PubMedCrossRefGoogle Scholar
  35. 35.
    • Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010;75(20):1766–72. Although not specifically studying MCI, the authors have performed an interesting study measuring α-synuclein oligomers in CSF, a potential predictor of cognitive impairment and dementia in PD.PubMedCrossRefGoogle Scholar
  36. 36.
    The Lancet Neurology. Biomarker promise for Parkinson’s disease. Lancet Neurol. 2010;9(12):1139.PubMedCrossRefGoogle Scholar
  37. 37.
    •• Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain. 2010;133(Pt 6):1747–54. This carefully designed study is among the first to suggest a possible cholinergic deficit related to olfactory dysfunction, a very early marker of PD, and cognitive functioning in non-demented PD patients.PubMedCrossRefGoogle Scholar
  38. 38.
    Kehagia AA, Murray GK, Robbins TW. Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation. Curr Opin Neurobiol. 2010;20(2):199–204.PubMedCrossRefGoogle Scholar
  39. 39.
    Whittington CJ, Podd J, Stewart-Williams S. Memory deficits in Parkinson’s disease. J Clin Exp Neuropsychol. 2006;28(5):738–54.PubMedCrossRefGoogle Scholar
  40. 40.
    • Bronnick K, Alves G, Aarsland D, et al. Verbal memory in drug-naive, newly diagnosed Parkinson’s disease. The retrieval deficit hypothesis revisited. Neuropsychology. 2010;25(1):114–24. This is one of the most detailed studies of memory functioning in nearly 200 de novo PD patients.CrossRefGoogle Scholar
  41. 41.
    Zgaljardic DJ, Borod JC, Foldi NS, Mattis P. A review of the cognitive and behavioral sequelae of Parkinson’s disease: relationship to frontostriatal circuitry. Cogn Behav Neurol. 2003;16(4):193–210.PubMedCrossRefGoogle Scholar
  42. 42.
    Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson’s disease. Mov Disord. 2007;22(9):1272–7.PubMedCrossRefGoogle Scholar
  43. 43.
    • Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord. 2009;24(8):1103–10. The authors carefully compare the strengths and limitations of various cognitive screening scales for use in patients with PD.PubMedCrossRefGoogle Scholar
  44. 44.
    Muslimovic D, Schmand B, Speelman JD, de Haan RJ. Course of cognitive decline in Parkinson’s disease: a meta-analysis. J Int Neuropsychol Soc. 2007;13(6):920–32.PubMedCrossRefGoogle Scholar
  45. 45.
    • Muslimovic D, Post B, Speelman JD, et al. Cognitive decline in Parkinson’s disease: a prospective longitudinal study. J Int Neuropsychol Soc. 2009;15(3):426–37. This is one of the most detailed studies exploring the course of a variety of cognitive domains in PD, including a group followed from time of diagnosis.PubMedCrossRefGoogle Scholar
  46. 46.
    Aarsland D, Muniz G, Matthews F. Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord. 2011;26(2):334.Google Scholar
  47. 47.
    •• Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(Pt 11):2958–69. This is the most carefully conducted study of the course and predictors of cognitive decline in a cohort including an incident PD cohort, adding genetic subtyping to the potential demographic and clinical predictors.PubMedCrossRefGoogle Scholar
  48. 48.
    Bangen KJ, Jak AJ, Schiehser DM, et al. Complex activities of daily living vary by mild cognitive impairment subtype. J Int Neuropsychol Soc. 2010;16(4):630–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson’s disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol. 2005;18(3):149–54.PubMedCrossRefGoogle Scholar
  50. 50.
    Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord. 2006;21(8):1123–30.PubMedCrossRefGoogle Scholar
  51. 51.
    • Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8. Although not including MCI subjects, this is the first study demonstrating efficacy of memantine for patients with Lewy body dementia.PubMedCrossRefGoogle Scholar
  52. 52.
    van Laar T, De Deyn PP, Aarsland D, et al. Effects of cholinesterase inhibitors in parkinson’s disease dementia: a review of clinical data. CNS Neurosci Ther. 2010. doi:10.1111/j.1755-5949.1010.00166.x.
  53. 53.
    • Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–55. This is the first study suggesting that a noradrenergic drug may improve cognition in non-demented PD patients, although cognition was not the primary outcome measure.PubMedCrossRefGoogle Scholar
  54. 54.
    Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738–45.PubMedCrossRefGoogle Scholar
  55. 55.
    Mamikonyan E, Moberg PJ, Siderowf A, et al. Mild cognitive impairment is common in Parkinson’s disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord. 2009;15(3):226–31.PubMedCrossRefGoogle Scholar
  56. 56.
    Sollinger AB, Goldstein FC, Lah JJ, et al. Mild cognitive impairment in Parkinson’s disease: subtypes and motor characteristics. Parkinsonism Relat Disord. 2010;16(3):177–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Dag Aarsland
    • 1
    • 5
  • Kolbjørn Brønnick
    • 2
  • Tormod Fladby
    • 3
    • 4
  1. 1.Centre for Age-Related Diseases, Division of PsychiatryStavanger University HospitalStavangerNorway
  2. 2.Norwegian Centre for Movement DisordersStavanger University HospitalStavangerNorway
  3. 3.Department of NeurologyAkershus University HospitalLørenskogNorway
  4. 4.Faculty Division Akershus University HospitalUniversity of OsloOsloNorway
  5. 5.Karolinska Institutet, Department NVS, KI Alzheimer Disease Research CenterStockholmSweden

Personalised recommendations